Weight Loss

During our physician-supervised program, you will receive a subcutaneous injection once weekly, preferably on the same day each week, to help reduce your appetite. Your dose will be adjusted based on your progress. Most likely, your dosage will be increased monthly until you reach your goal weight, at which point you will be transitioned off the medication.

Semaglutide is a glucagon-like peptide-1, a GLP-1 receptor agonist that was initially developed for diabetes management. However, during clinical trials, it was observed that patients using semaglutide experienced significant weight loss as a side effect. It is believed to act on the brain’s appetite-regulating centers, leading to decreased hunger and increased fullness after meals.

Studies have demonstrated that Semaglutide can promote substantial weight loss, often exceeding 10% of initial body weight. This remarkable effect has positioned Semaglutide as a game-changer in the field of obesity treatment. The FDA approved Semaglutide at a higher dose for weight management in 2021, paving the way for a novel non-surgical approach to address the global obesity epidemic.

Terzepatide is a glucose-dependent insulinotropic polypeptide, a glucagon-like peptide-1 or GLP-1 and glucagon triple agonist. Like semaglutide, Terzepatide was primarily developed to treat type 2 diabetes. However, preclinical and early-phase clinical trials have exhibited its potential in promoting weight loss as well.

The triple agonistic action of Terzepatide allows it to target multiple physiological pathways involved in appetite regulation and glucose metabolism. By engaging GIP, GLP-1, and glucagon receptors, Terzepatide can reduce food intake, enhance safety, and improve insulin sensitivity, making it a promising candidate for obesity management.

Suggestions While Treating: 

1. Eat a high-fiber diet of fruits and veggies.
2. Avoid high-fat and processed foods.
3. Limit alcohol and sugar sodas.
4. Avoid eating after 7 PM.
5. 0–45 minutes of cardio exercise 3x/week.
6. Drink at least 64 oz. of water daily.

Both Semaglutide and Terzepatide have undergone rigorous clinical trials to assess their efficacy and safety as weight loss agents. In one landmark trial, the STEP 1 study, participants receiving Semaglutide experienced an average weight loss of around 15% over 68 weeks. This far surpassed the results achieved with other weight loss medications or interventions, underscoring Semaglutide's potential as a groundbreaking therapy. Similarly, Terzepatide has demonstrated encouraging results in early clinical trials. In a phase 2 trial, participants receiving Terzepatide lost a significant amount of weight compared to the control group.

As with any medication, safety is a critical concern when considering long-term usage. Fortunately, both Semaglutide and Terzepatide have shown a favorable safety profile in clinical trials. Common side effects include mild gastrointestinal disturbances, such as nausea, diarrhea, and constipation. Other less common side effects include abdominal pain, headache, fatigue, stomach ache, dizziness, belching, hypoglycemia, flatulence, gastroenteritis, and gastroesophageal reflux disease.

For medical weight loss assistance you can trust, book your appointment online or call us at 941-761-4994 today.